BPC-157 Dosage Chart
Quick-reference protocols for tendon, gut, post-surgical, and systemic use, plus reconstitution math for the 5 mg and 10 mg vials.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
BPC-157 is one of the most-searched research peptides in the recovery space. Because it has no FDA-approved human dosing label, every protocol you'll see is extrapolated from preclinical work (primarily Sikiric and colleagues at the University of Zagreb) and from clinician practice in 503A/503B compounding settings. The ranges below reflect the most commonly cited protocols across published reviews and US peptide-therapy practice in 2026 — they are not prescriptive and they are not validated by formal human dose-ranging trials.
BPC-157 at a Glance
| Typical dose range | 200–500 mcg/day (subcutaneous); 250–500 mcg 1–2× daily oral |
|---|---|
| Route | Subcutaneous injection (most common) or oral capsule (for gut indications) |
| Frequency | Once or twice daily |
| Cycle length | 4–8 weeks on, 2–4 weeks off (some protocols continuous for chronic gut conditions) |
| FDA status | Not FDA-approved. Available via 503A/503B compounding pharmacy with provider prescription. |
| Source quality | Animal data robust (Sikiric et al., 1990s–present). Human RCT data minimal — protocols are practitioner-derived. |
| Common vial size | 5 mg or 10 mg lyophilized powder |
BPC-157 Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for BPC-157. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL (250 mcg per 0.1 mL) |
|
| 5 mg | 5 mL | 1 mg/mL (100 mcg per 0.1 mL) |
|
| 10 mg | 2 mL | 5 mg/mL (500 mcg per 0.1 mL) |
|
U-100 syringe reference: 100 units = 1.0 mL. So 10 units = 0.1 mL, 25 units = 0.25 mL, 50 units = 0.5 mL. Always confirm the actual concentration printed on your pharmacy label before drawing a dose — vial sizes and reconstitution volumes vary by compounder.
BPC-157 Dosing by Use Case
Commonly cited protocols vary by what BPC-157 is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Tendon / ligament (Achilles, rotator cuff, tennis elbow) | 250 mcg | 1–2× daily, subQ near injury site | 4–6 weeks | Subcutaneous near (not into) the affected tendon is the common compromise between systemic and local delivery. |
| Gut / IBS, IBD, gastritis | 250–500 mcg | 2× daily, oral preferred | 6–8 weeks | BPC-157 is acid-stable, making oral capsules viable for gut-targeted use. |
| Post-surgical recovery | 250–500 mcg | 1–2× daily, subQ | 2–4 weeks starting 24–48 hr post-op | Coordinate with surgeon; avoid in active bleeding or anticoagulation contexts. |
| Systemic anti-inflammatory / general use | 250 mcg | Once daily, abdominal subQ | 4–6 weeks | Default protocol when no specific tissue target. |
Stacking BPC-157
BPC-157 is most commonly stacked with TB-500 for soft-tissue and tendon recovery — the pairing is known as the Wolverine Stack. It is also paired with KPV for gut-focused protocols, and occasionally with GHK-Cu for systemic recovery.
BPC-157 is generally well-tolerated in published animal and clinical-practice data, but human safety data is limited.
- •No formal human maximum tolerated dose has been established. Animal studies tested up to 10 mg/kg without acute toxicity, but this does not establish safety in humans.
- •Possible side effects in practice: mild GI upset, transient blood pressure changes, injection-site reactions.
- •Theoretical concern: BPC-157 is angiogenic. Most clinicians avoid it in patients with active or recent malignancy until more data exists.
- •Do not co-mix BPC-157 and TB-500 in the same syringe without explicit pharmacy guidance — sterility and stability questions arise.
- •Pause the cycle and consult your provider if systemic side effects emerge.
- •You have an active or recent cancer diagnosis (relative contraindication — discuss with your oncologist)
- •You are pregnant, breastfeeding, or trying to conceive (no human safety data)
- •You have an allergy to any compounded carrier or preservative in the formulation
BPC-157 Dosing FAQ
Reconstitute the vial, then divide your prescribed dose (in mcg) by the concentration (in mcg/mL), then multiply by 100 to get insulin-syringe units. For a 5 mg vial reconstituted with 2 mL bacteriostatic water (2,500 mcg/mL), 250 mcg = 0.1 mL = 10 units on a U-100 syringe.
For gut indications (IBS, IBD, gastritis), oral BPC-157 is widely used because the peptide is acid-stable and acts directly on GI tissue. For systemic indications like tendon repair, subcutaneous injection is the more common protocol because direct evidence of systemic bioavailability from oral dosing in humans is limited.
Anecdotal reports describe gut symptom improvement within days to two weeks; tendon and ligament responses are typically reported over 3–6 weeks. Tendon biology is slow regardless of pro-healing signals — most practitioners cycle for at least 4 weeks before assessing response.
Most clinicians administer BPC-157 subcutaneously near the affected tendon rather than intra-tendinous. Direct intra-tendinous injection is generally not recommended outside of specific image-guided procedures by sports medicine specialists.
BPC-157 is reported to act faster on inflammation and gut/vascular tissue; TB-500 is reported to act more on cell migration, actin regulation, and broader tissue regeneration. They are commonly stacked because the mechanisms are seen as complementary.
Sources
Related Dosage Charts
Want the full BPC-157 guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for BPC-157 therapy.
See BPC-157 guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.